Samuel Whittle

Samuel Whittle

Rheumatologist & Epidemiologist

Rheumatology Unit,
The Queen Elizabeth Hospital
28 Woodville Road, Woodville South, South Australia 5011
+618 8222 6688
samuel.whittle@sa.gov.au
sam.xyz

Qualifications

  • Fellow of the Royal Australasian College of Physicians, 2004
  • Bachelor of Medicine, Bachelor of Surgery (Honours), University of Adelaide 1997
  • Master of Clinical Epidemiology (with Distinction), University of Newcastle, 2010

Appointments

  • Senior Consultant Rheumatologist, The Queen Elizabeth Hospital
  • Senior Lecturer, The University of Adelaide
  • ANZMUSC Practitioner Fellow
  • Adjunct Senior Research Fellow, Monash University

Professional Service

  • President, Australian Rheumatology Association South Australian Branch (2019-21)
  • Board Member, Australian Rheumatology Association (2019 - 2021)
  • Executive Committee Member, Australia & New Zealand Musculoskeletal Clinical Trials Network (ANZMUSC) (2014-present)
  • Member, Cochrane Musculoskeletal Editorial Board (2019-2024)
  • Steering Committee, South Australian Commission on Excellence and Innovation in Health Statewide Chronic Pain Clinical Network (2021 - present)
  • Other Australian Rheumatology Association Committees:
    • Chair, Clinical Resources Committee (2019 - present)
    • ASM Programme Committee (2016 - present)
    • Financial Advisory Committee (2014-2020)
    • Honorary Treasurer (2016-2018)
    • Sponsor Liaison Committee (2016 - 2020)
    • Representative to Asia-Pacific League of Associations for Rheumatology (APLAR) (2008-2018)
    • Convenor, Annual Scientific Meeting, Adelaide 2015
    • Electronic Communications Committee (2008-12)
  • Associate Editor, International Journal of Rheumatic Diseases (2008 - present)
  • Arthritis SA Education, Research & Advocacy Committee (2012 – present)
  • Member, Thrombosis and Haemostasis Society of Australia and New Zealand (THANZ) Vaccine-Induced Immune Thrombotic Syndrome Communications Committee 2021
  • Member, Rheumatology Expert Writing Group, Rheumatology Guidelines 4th Edition 2021
  • Co-ordinator, TQEH Med IV Rheumatology Teaching Programme (2008-present)
  • Steering Committee Member, National Strategic Action Plan for Arthritis (2018)
  • Fellow, Shoulder Disorders Working Group, OMERACT (2017 - 2018)
  • Chair of Judging Panel, RACP South Australian Trainee Research Awards 27 Oct 2020
  • Member, Rheumatology Expert Writing Group, Rheumatology Guidelines 3rd Edition 2015-16
  • Grant Reviews:
    • NHMRC Grant Review Panel (2011 & 2012)
    • NHMRC External Assessor (2011, 2013, 2014)
    • NZ Health Research Council Biomedical/clinical Science Assessing Committee (2019)
    • Arthritis Research UK (2016)
    • Dutch Organisation for Health Research and Development (ZonMw) (2014)

Grants

  • ANZMUSC Practitioner Fellowship 2018-2020 ($398,520)
  • Therapeutic Guidelines Ltd (TGL)/RACGP Foundation Research Grant (TGL-03) (CI): Use of Osteoarthritis Guidelines in General Practice: An Analysis of Work-as-Done Using the Functional Resonance Analysis Method. 2020-21. ($19,968)
  • Arthritis Australia Project Grant 2018 (CIB): Community perceptions of rheumatoid arthritis pharmacotherapy: an analysis of social media platforms ($35,000)
  • Australian Commonwealth Government Value in Prescribing Program: Biological Disease-Modifying Anti-Rheumatic Drugs 2019-2022 (GO1512) (Consortium Member) ($8,411,402)
  • MRFF Efficient Use of Existing Medicines 2020 (APP2007502) (CII): Cost-utility comparison of down-titration strategies for safer and more efficient use of biologics in adults with rheumatoid arthritis and psoriatic arthritis, ($2.7M)

Prizes

  • Best Clinical Science Free Paper, Australian Rheumatology Association Annual Scientific Meeting, Auckland, May 2017 (The DAS28-P Index as a predictor of poor subjective response to DMARD therapy in early rheumatoid arthritis)
  • Tom Highton Award for Best Presentation at the Annual Scientific Meeting of the New Zealand Rheumatology Association, Auckland, May 2017 (The DAS28-P Index as a predictor of poor subjective response to DMARD therapy in early rheumatoid arthritis)
  • Best Poster, OMERACT 2018, Terrigal NSW, May 2018 (Instruments Measuring Pain in Shoulder Disorders)

Publications

  1. Sharma C, Whittle S, Haghighi P, Burstein F, Keen H. Response to ‘Correspondence on ‘Mining social media data to investigate patient perceptions regarding DMARD pharmacotherapy for rheumatoid arthritis’’ by Reuter et al. Ann Rheum Dis. 2021 Feb. doi.org/10.1136/annrheumdis-2020-219815
  2. Ferreira GE, Zadro JR, O’Keeffe M, Buchbinder R, Maher C, Latimer J, et al. Challenges faced by musculoskeletal health research in Australia and New Zealand due to the COVID-19 pandemic. Intern Med J. 2021;51: 622.
  3. Venter G, Tieu J, Black R, Lester S, Leonardo N, Whittle SL, et al. Perspectives of Glucocorticoid Use in Patients with Rheumatoid Arthritis. ACR Open Rheumatology. 2021; 3(4): 231-238. doi:10.1002/acr2.11234
  4. Adams L, Lester S, Hoon E, van der Haak H, Proudman C, Hall C, Whittle S, Proudman S, Hill C. Patient satisfaction and acceptability with telehealth at specialist medical outpatient clinics during the COVID-19 pandemic in Australia. Internal Medicine Journal 2021. In press.
  5. Davis CR, Ruediger CD, Dyer KA, Lester S, Graf SW, Kroon FPB, Whittle SL, Hill CL. Colchicine is not effective for reducing osteoarthritic hand pain compared to placebo: a randomised, placebo-controlled trial (COLAH). Osteoarthritis Cartilage. 2020. doi:10.1016/j.joca.2020.11.002
  6. Buchbinder R, Ramiro S, Huang H, Gagnier JJ, Jia Y, Whittle SL. Measures of adult shoulder function. Arthritis Care Res (Hoboken). 2020 Oct;72 Suppl 10:250-293. doi: 10.1002/acr.24230
  7. Sharma C, Whittle S, Haghighi PD,Burstein F, Keen H. Sentiment analysis of social media posts on pharmacotherapy: A scoping review. Pharmacol Res Perspect. 2020;e00640. https://doi.org/10.1002/prp2.640
  8. Sharma C, Whittle SL, Delir Haghighi P, Burstein F, Sa’adon R, Keen H. Mining Social Media Data to Investigate Patient Perceptions Regarding DMARD Pharmacotherapy for Rheumatoid Arthritis. Ann Rheum Dis 2020. https://doi:10.1136/annrheumdis-2020-217333.
  9. Lowe J, Briggs AM, Whittle S, Stephenson MD. A systematic review of the effects of probiotic administration in inflammatory arthritis. Complement Ther Clin Pract. 2020; 101207.
  10. Leonardo N, Lester S, Graham M, Barrett C, Whittle S, Rowett D, et al. Selection and perception of methotrexate treatment information in people with rheumatoid arthritis. Int J Rheum Dis. 2020;15: 1586.
  11. Putman MS, Sufka P, Whittle S, Robinson PC. European consensus statements for interstitial lung disease in systemic sclerosis [letter]. The Lancet Rheumatology. 2020;2: e317–e318.
  12. Hazlewood GS, Whittle SL, Kamso MM, Akl EA, Wells GA, Tugwell P, et al. Disease‐modifying anti‐rheumatic drugs for rheumatoid arthritis: a systematic review and network meta‐analysis. Cochrane Database Syst Rev. 2020 [cited 8 Apr 2020]. doi:10.1002/14651858.CD013562
  13. Khadra Y, Walker JG, Hakendorf P, Proudman S, Rischmueller M, Hill CL, Whittle S, et al. Scleroderma Renal Crisis: Observations from the South Australian Scleroderma Register. Intern Med J. 2020. doi:10.1111/imj.14772
  14. Røe Y, Buchbinder R, Grotle M, Whittle S, Ramiro S, Huang H, et al. What do the OMERACT Shoulder Core Set candidate instruments measure? An analysis using the refined ICF linking rules. J Rheumatol. 2020. doi:10.3899/jrheum.190832
  15. Leonardo N, Lester S, Whittle S, Rischmueller M. Review of gout clinic in a tertiary hospital setting. Intern Med J. 2020;50: 117–120.
  16. Szeto C-C, Sugano K, Wang J-G, Fujimoto K, Whittle S, Modi GK, et al. Non-steroidal anti-inflammatory drug (NSAID) therapy in patients with hypertension, cardiovascular, renal or gastrointestinal comorbidities: joint APAGE/APLAR/APSDE/APSH/APSN/PoA recommendations. Gut. 2020; gutjnl–2019–319300.
  17. Cai K, Whittle SL, Richards BL, Ramiro S, Falzon L, Buchbinder R. Marine oil supplements for rheumatoid arthritis. Cochrane Database of Systematic Reviews 2019, Issue 12. Art. No.: CD010250. DOI: 10.1002/14651858.CD010250.pub2.
  18. Ng J, Little CB, Woods S, Whittle S, Lee FY, Gronthos S, et al. Stem Cell Directed Therapies for Osteoarthritis: the promise and the practice: Concise Review. Stem Cells. 2019. doi:10.1002/stem.3139
  19. Whittle SL, Johnston RV, McDonald S, Paterson KL, Buchbinder R. Autologous blood product injections including platelet-rich plasma for osteoarthritis of the knee. [protocol]. Cochrane Database Syst Rev. 2019;24: 166.
  20. Whittle SL, Johnston RV, McDonald S, Worthley D, Mark Campbell T, Buchbinder R. Stem cell injections for osteoarthritis of the knee. [protocol]. Cochrane Database Syst Rev. John Wiley & Sons, Ltd; 2019; doi:10.1002/14651858.CD013342
  21. Chan FLY, Lester S, Whittle SL, Hill CL. The utility of ESR, CRP and platelets in the diagnosis of GCA. BMC Rheumatology. 2019;3: 14.
  22. Page MJ, O’Connor DA, Malek M, Haas R, Beaton D, Huang H, Ramiro S, Richards P, Voshaar MJ, Shea B, Verhagen AP, Whittle SL, van der Windt DA, Gagnier JJ, Buchbinder R. Patients’ experience of shoulder disorders: a systematic review of qualitative studies for the OMERACT Shoulder Core Domain Set. Rheumatology. 2019; doi:10.1093/rheumatology/kez046
  23. Tam LS, Wei JC-C, Aggarwal A, Baek HJ, Cheung PP, Chiowchanwisawakit P, Dans L, Gu J, Hagino N, Kishimoto M, Reyes HM, Soroosh S, Stebbings S, Whittle SL, Yeap SS, Lau CS. 2018 APLAR axial spondyloarthritis treatment recommendations. Int J Rheum Dis. 2019; doi:10.1111/1756-185X.13510
  24. Ramiro S, Page MJ, Whittle SL, Huang H, Verhagen AP, Beaton D, et al. The Omeract Core Domain Set for Clinical Trials of Shoulder Disorders. J Rheumatol. 2019; doi:10.3899/jrheum.181070
  25. Wilsdon TD, Whittle SL, Thynne TR, Mangoni AA. Methotrexate for psoriatic arthritis. Cochrane Database Syst Rev. 2019;1: CD012722.
  26. Bourne AM, Johnston RV, Cyril S, Briggs AM, Clavisi O, Duque G, Harris IA, Hill C, Hiller C, Kamper SJ, Latimer J, Lawson A, Lin C-WC, Maher C, Perriman D, Richards BL, Smitham P, Taylor WJ, Whittle S, Buchbinder R. Scoping review of priority setting of research topics for musculoskeletal conditions. BMJ Open. 2018;8: e023962.
  27. Buchbinder R, Bourne A, Latimer J, Harris I, Whittle S, Richards B, et al. Early development of the Australia & New Zealand Musculoskeletal (ANZMUSC) Clinical Trials Network. Intern Med J. 2018; doi:10.1111/imj.14191
  28. Chua AC, Venkataraman K, Whittle SL. Occipital condyle syndrome mimicking giant cell arteritis as the first manifestation of disseminated malignancy. Internal Medicine Journal 2018; 48(9): 1163-4. http://dx.doi.org/10.1111/imj.14022
  29. Lowe J, Briggs A, Whittle S, Hoon E, Stephenson M. Effectiveness of probiotics in the management of inflammatory arthritis: a systematic review protocol. JBI Database System Rev Implement Rep. 2018; doi:10.11124/JBISRIR-2017-003692
  30. Pisaniello HL, Lester S, Gonzalez-Chica D, Stocks N, Longo M, Sharplin G, Dal Grande E, Gill T, Whittle SL, Hill C. Gout prevalence and predictors of urate-lowering therapy use: results from a population-based study. Arthritis Res Ther (2018). Arthritis Res Ther. 2018 Jul 11;20(1):143. doi: 10.1186/s13075-018-1633-9.
  31. Black RJ, Lester S, Buchbinder R, Barrett C, Lassere M, March L, Whittle S, Hill CL. Factors associated with oral glucocorticoid use in patients with rheumatoid arthritis: a drug use study from a prospective national biologics registry. Arthritis Res Ther (2017); 19:253. DOI 10.1186/s13075-017-1461-3
  32. Wilsdon TD, Whittle SL, Thynne TRJ, Mangoni AA. Methotrexate for psoriatic arthritis (Protocol). Cochrane Database of Systematic Reviews 2017, Issue 7. Art. No.: CD012722. DOI: 10.1002/14651858.CD012722.
  33. Goldacre, B., Whittle, S, Ernst, E. & Mendel, J. Authors’ reply to Beales. BMJ 356, j1196 (2017).
  34. Delir Haghighi P, Kang Y-B, Buchbinder R, Burstein F, Whittle S. Investigating Subjective Experience and the Influence of Weather Among Individuals With Fibromyalgia: A Content Analysis of Twitter. JMIR Public Health and Surveillance 3, e4 (2017).
  35. Truong SL, Saad NF, Robinson PC, Cowderoy G, Lim I, Schachna L, Stebbings S, Stuckey S, Taylor AL, Whittle SL, Zochling J, Bird P, Brown MA. Consensus statements on the imaging of axial spondyloarthritis in Australia and New Zealand. J Med Imaging Radiat Oncol. 2016 Dec 19. doi:10.1111/1754-9485.12573.
  36. Mendel J, Goldacre B, Ernst E, Whittle S. Problems with ethical approval and how to fix them: lessons from three trials in rheumatoid arthritis. BMJ. 2016 Sep 9;i4626.
  37. Pisaniello HL & Whittle SL. Fibromyalgia: Finding the Silver Lining around a Common Chronic Pain Disorder. Medicine Today 2016; 17(12): 54-56
  38. Milman N, Hill CL, Whittle SL, El Sayad J, Wells GA. Methotrexate for giant cell arteritis (protocol). In: Cochrane Database of Systematic Reviews [Internet]. John Wiley & Sons, Ltd; 2016 [cited 2016 May 26]. Available from: http://onlinelibrary.wiley.com.proxy.library.adelaide.edu.au/doi/10.1002/14651858.CD005323.pub3/abstract
  39. Milman N, Whittle SL, Hill CL, El Sayad J, Wells GA. Methotrexate for polymyalgia rheumatica (protocol). In: Cochrane Database of Systematic Reviews [Internet]. John Wiley & Sons, Ltd; 2016 [cited 2016 May 26]. Available from: http://onlinelibrary.wiley.com.proxy.library.adelaide.edu.au/doi/10.1002/14651858.CD005325.pub3/abstract
  40. Ting KH, Hill CL, Whittle SL. Quality of reporting of interventional animal studies in rheumatology: a systematic review using the ARRIVE guidelines. Int J Rheum Dis. 2015 Jun;18(5):488-94. doi: 10.1111/1756-185X.12699.
  41. Graf SW, Whittle SL, Wechalekar MD, Moi JHY, Barrett C, Hill CL, Littlejohn G, Lynch N, Major G, Taylor AL, Buchbinder R, Zochling J. Australian and New Zealand Recommendations for the Diagnosis and Management of Gout: integrating systematic literature review and expert opinion in the 3e initiative. Int J Rheum Dis. 2015 Mar;18(3):341-51. doi: 10.1111/1756-185X.12557. Epub 2015 Apr 17.
  42. Ting K, Graf SW & Whittle SL. Update on the diagnosis and management of gout. Med J Aust 2015; 203 (2): 86-88.
  43. Graf SW & Whittle SL. Isotretinoin-induced skeletal hyperostosis. Springerplus 2014 Nov 27;3(1):698.
  44. Whittle S & Buchbinder R. In The Clinic: Rotator Cuff Disease. Ann Intern Med. 2015 Jan 6;162(1):ITC1.
  45. Moghaddami M, James M, Whittle SL, Cleland LG. Synovial fluid myeloid dendritic cells display important differences compared to monocyte-derived dendritic cells prepared in vitro. Clin Trans Immunol. 2014 Aug 8;3(8):e23.
  46. Richards BL, Whittle SL, Buchbinder R, Barrett C, Lynch N, Major G, et al. Australian and New Zealand evidence-based recommendations for pain management by pharmacotherapy in adult patients with inflammatory arthritis. International Journal of Rheumatic Diseases [Internet]. 2014 [cited 2014 Jun 3]; Available from: http://onlinelibrary.wiley.com/doi/10.1111/1756-185X.12388/full
  47. Robinson PC, Bird P, Lim I, Saad N, Schachna L, Taylor AL, Whittle SL, Brown MA. Consensus statement on the investigation and management of non-radiographic axial spondyloarthritis (nr-axSpA). International Journal of Rheumatic Diseases. 2014 (epub ahead of print; DOI 10.1111/1756-185X.12358)
  48. Bourne, A. M., Whittle, SL, Richards, B. L., Maher, C. G. & Buchbinder, R. The scope, funding and publication of musculoskeletal clinical trials performed in Australia. Med. J. Aust. 200(2): 88-91, (2014).
  49. Whittle SL, Colebatch AN, Adams K, Englbrecht M, Hazlewood G, et al. Multinational Evidence-Based Recommendations for Pain Management by Pharmacotherapy in Inflammatory Arthritis: Integrating Systematic Literature Research and Expert Opinion of a Broad Panel of Rheumatologists in the 3e Initiative. Rheumatology (March 24, 2012). Available from: http://rheumatology.oxfordjournals.org/content/early/2012/03/23/rheumatology.kes032.
  50. Whittle SL, Buchbinder R. Opioid analgesics for rheumatoid arthritis pain. JAMA 309, 485–486 (2013).
  51. Graf, SW, Buchbinder, R, Zochling, J & Whittle, SL. The accuracy of methods for urate crystal detection in synovial fluid and the effect of sample handling: A systematic review. Clin Rheumatol. 2013 Feb;32(2):225-32.
  52. Whittle SL, Richards, B. L., Ramiro, S. & Buchbinder, R. Fish oil supplements for rheumatoid arthritis [protocol]. In: Cochrane Database of Systematic Reviews (John Wiley & Sons, Ltd, 2012). at http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010250/abstract
  53. Whittle SL, Richards, BL, van der Heijde, DM. & Buchbinder, R. The efficacy and safety of opioids in inflammatory arthritis: a cochrane systematic review. J Rheumatol Suppl 90, 40–46 (2012).
  54. Richards, BL, Whittle SL, van der Heijde, DM & Buchbinder, R. Efficacy and safety of neuromodulators in inflammatory arthritis: a Cochrane systematic review. J Rheumatol Suppl 90, 28–33 (2012).
  55. Richards, BL, Whittle SL, van der Heijde, DM & Buchbinder, R. The efficacy and safety of antidepressants in inflammatory arthritis: a Cochrane systematic review. J Rheumatol Suppl 90, 21–27 (2012).
  56. Richards, BL,** Whittle SL**, van der Heijde, DM & Buchbinder, R. The efficacy and safety of muscle relaxants in inflammatory arthritis: a Cochrane systematic review. J Rheumatol Suppl 90, 34–39 (2012).
  57. Richards BL, Whittle SL, Buchbinder R. Neuromodulators for pain management in rheumatoid arthritis. Cochrane Database Syst Rev. 2012;1:CD008921.
  58. Richards BL, Whittle SL, Buchbinder R. Muscle relaxants for pain management in rheumatoid arthritis. Cochrane Database Syst Rev. 2012;1:CD008922.
  59. Wechalekar MD, Lester S, Proudman SM, Cleland LG, Whittle SL, Rischmueller M, et al. Active foot synovitis: Criteria for remission and disease activity underestimate foot involvement in rheumatoid arthritis. Arthritis & Rheumatism 2012; 64(5): 1316-1322
  60. Whittle SL, Richards BL, Husni E, Buchbinder R. Opioid therapy for treating rheumatoid arthritis pain. Cochrane Database Syst Rev. 2011;11:CD003113.
  61. Richards BL, Whittle SL, Buchbinder R. Antidepressants for pain management in rheumatoid arthritis. Cochrane Database Syst Rev. 2011;11:CD008920.
  62. Wechalekar MD, Rischmueller M, Whittle S, Burnet S, Hill CL. Prolonged remission of chronic reactive arthritis treated with three infusions of infliximab. J Clin Rheumatol. 2010 Mar;16(2):79–80.
  63. Katikireddi VS, Whittle SL, Hill CL. Tumour necrosis factor inhibitors and risk of serious infection in rheumatoid arthritis. Int J Rheum Dis. 2010 Feb 1;13(1):12–26.
  64. Whittle SL, Cole A, Lester S, Hill CL. Steroid sparing drug treatments for polymyalgia rheumatica [Protocol]. In: The Cochrane Collaboration, Hill CL, editors. Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd; 2009 [cited 2011 Apr 13]. Available from: http://onlinelibrary.wiley.com/o/cochrane/clsysrev/articles/CD005325/abstract.html
  65. Hill CL, Cole A, Lester S, Whittle SL. Steroid sparing drug treatments for giant cell arteritis [Protocol]. In: The Cochrane Collaboration, Hill CL, editors. Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd; 2009 [cited 2011 Apr 13]. Available from: http://onlinelibrary.wiley.com/o/cochrane/clsysrev/articles/CD005323/abstract.html
  66. Mangat P, Whittle S, Cleland L, Limaye V. Digital vasculitis: a late complication of anti-tumour necrosis factor alpha therapy. Clin. Rheumatol. 2008 Dec;27(12):1593–5.
  67. Whittle SL, Hughes RA. Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review. Rheumatology (Oxford). 2004 Mar;43(3):267–71.
  68. Whittle SL, Hughes RA. Methotrexate and folic acid: what is the optimal combination? (Letter). Rheumatology (Oxford). 2004 Aug; 43(8): 1061
  69. Whittle SL, James M, Cleland LG. Focus on Meloxicam (Review). Medicine Today 2002; 3(9): 73-76
  70. Edwards DJ, Whittle SL, Nissen MJ, Cohen B, Oakeshott RD, Keene GC. Radiographic changes in the knee after meniscal transplantation. An experimental study in a sheep model. Am J Sports Med. 1996 Apr;24(2):222–6.

Invited talks (last 5 years)

Joint Pain in Osteoarthritis
Global Year Against Pain in the Joints Public Forum
Australian Rheumatology Association Annual Scientific Meeting, Darwin, May 2016

Predictors of Response to Therapy in Psoriasis and Psoriatic Arthritis
Novartis Rheumatology and Dermatology Preceptorship. Sydney, 17th September 2016

Ankylosing Spondylitis: TNF Inhibition and Beyond
Novartis Rheumatology and Dermatology Preceptorship. Sydney, 18th September 2016

Chronic pain in rheumatology: fibromyalgia and beyond
Faculty of Pain Medicine Regional CME meeting, Adelaide, 7th November 2016

Fibromyalgia: A Rheumatological Construct?
Arthritis SA Health Professionals Conference, 23 June 2017

Fibromyalgia
Arthritis SA Community Seminar, 22 Oct 2017

ANZMUSC & Living Evidence: An Introduction
ANZMUSC Update Meeting, Sydney, 28 November 2018

Talking Fibromyalgia
Arthritis SA Community Seminar, 17 February 2019

Living Network Meta-analysis
Cochrane Webinar, 21 March 2019

Biologics in Rheumatic Diseases 2019: Spoiled for Choice
ASCEND Nurse Education Meeting, Adelaide, August 2019

On Building A Living Evidence Ecosystem in Musculoskeletal Disease
RACP SA Annual Scientific Meeting, Adelaide, November 2019

Development of the ANZMUSC Living Guidelines Conflict of Interest Process
ANZMUSC Clinical Trials Network Mid-Year Scientific Meeting, 6 October 2020

An Australian Living Guideline for the Pharmacological Management of Inflammatory Arthritis: bDMARD Tapering Recommendations
Australian Rheumatology Association Webinar Series, 16th November 2020

On Building a Living Evidence Ecosystem in Musculoskeletal Disease
Australasian Society of Clinical Immunology and Allergy Educational Meeting, Adelaide, 15 December 2020

An Australian Living Guideline for the Pharmacological Management of Inflammatory Arthritis: Recommendations on Opioids for Pain in Inflammatory Arthritis
Australian Rheumatology Association Webinar Series, 16th February 2021

An Australian living guideline for the pharmacological management of inflammatory arthritis
Cabrini Research Sessions, 12th May 2021

Invited international speaker,
New Zealand Rheumatology Association Annual Scientific Meeting, Dunedin NZ, August 2021